EA200802390A1 - Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их - Google Patents

Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их

Info

Publication number
EA200802390A1
EA200802390A1 EA200802390A EA200802390A EA200802390A1 EA 200802390 A1 EA200802390 A1 EA 200802390A1 EA 200802390 A EA200802390 A EA 200802390A EA 200802390 A EA200802390 A EA 200802390A EA 200802390 A1 EA200802390 A1 EA 200802390A1
Authority
EA
Eurasian Patent Office
Prior art keywords
aziridelepotilon
consents
analogues
pharmaceutical compositions
compositions containing
Prior art date
Application number
EA200802390A
Other languages
English (en)
Inventor
Грегори Д. Вит
Фрэнсис И. Ли
Кристофер П. Лимон
Ионтчо Р. Влахов
Original Assignee
Бристол-Маерс Сквибб Компани
Эндоцит, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани, Эндоцит, Инк. filed Critical Бристол-Маерс Сквибб Компани
Publication of EA200802390A1 publication Critical patent/EA200802390A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

Настоящее изобретение относится к конъюгатам, содержащим фолат, или аналог, или его производное и азиридиниловый аналог эпотилона, как в дальнейшем описано в настоящем изобретении, и/или их фармацевтически приемлемые соли и/или сольваты, пригодные для лечения рака или других, связанных с фолат-рецептором состояниями.
EA200802390A 2006-05-25 2007-05-25 Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их EA200802390A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80836706P 2006-05-25 2006-05-25
PCT/US2007/069740 WO2007140298A1 (en) 2006-05-25 2007-05-25 Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same

Publications (1)

Publication Number Publication Date
EA200802390A1 true EA200802390A1 (ru) 2009-06-30

Family

ID=38461157

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200802390A EA200802390A1 (ru) 2006-05-25 2007-05-25 Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их

Country Status (16)

Country Link
US (1) US20070275904A1 (ru)
EP (1) EP2023960A1 (ru)
JP (1) JP2009538350A (ru)
KR (1) KR20090025267A (ru)
CN (1) CN101495154A (ru)
AR (1) AR062448A1 (ru)
AU (1) AU2007267536A1 (ru)
BR (1) BRPI0712165A2 (ru)
CA (1) CA2657276A1 (ru)
EA (1) EA200802390A1 (ru)
IL (1) IL195237A0 (ru)
MX (1) MX2008014788A (ru)
NO (1) NO20084752L (ru)
PE (1) PE20080102A1 (ru)
TW (1) TW200813065A (ru)
WO (1) WO2007140298A1 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1389209B1 (en) * 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
CA2484640C (en) * 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
NZ541846A (en) 2003-01-27 2008-12-24 Endocyte Inc Vitamin receptor binding drug delivery conjugates
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
EP1863816B1 (en) 2005-03-16 2014-06-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
ES2468240T3 (es) 2005-08-19 2014-06-16 Endocyte, Inc. Conjugados de ligando de múltiples fármacos
EP2382995A3 (en) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CA2680535C (en) 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
WO2008147941A1 (en) * 2007-05-25 2008-12-04 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
BR112013026680A2 (pt) * 2011-08-15 2016-12-27 Univ City New York Res Found composto, método de tratamento de uma doença inflamatória e composição farmacêutica
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
MX2015004757A (es) 2012-10-16 2015-07-17 Endocyte Inc Conjugados de suministro de farmacos que contienen aminoacidos no naturales y metodo para usarlos.
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
WO2014101134A1 (zh) * 2012-12-28 2014-07-03 Yan Wenguang 叶酸衍生物及其制备方法和应用
CN109316605B (zh) * 2014-01-20 2023-07-14 博瑞生物医药（苏州）股份有限公司 叶酸受体结合配体-药物偶联物
KR102494646B1 (ko) 2014-03-20 2023-01-31 브리스톨-마이어스 스큅 컴퍼니 안정화된 피브로넥틴 기반 스캐폴드 분자
UY36404A (es) 2014-11-21 2016-06-01 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN
CA2968382A1 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
KR102632418B1 (ko) 2014-11-25 2024-01-31 브리스톨-마이어스 스큅 컴퍼니 영상화를 위한 신규 pd-l1 결합 폴리펩티드
JP2018510864A (ja) 2015-03-10 2018-04-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体
MY188049A (en) 2015-05-29 2021-11-12 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
EP3733698A1 (en) 2015-09-23 2020-11-04 Bristol-Myers Squibb Company Glypican-3 binding fibronectin based scafflold molecules
MA43178A (fr) 2015-10-16 2018-09-12 Univ Rice William M Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci
BR112018012524A2 (pt) 2015-12-21 2018-12-11 Bristol Myers Squibb Co anticorpos variantes para conjugação sítio-específica
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
US20190218294A1 (en) 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
KR20200013241A (ko) 2017-05-25 2020-02-06 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
US20220106400A1 (en) 2018-11-28 2022-04-07 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
HRP20230500T1 (hr) 2018-11-30 2023-07-21 Bristol-Myers Squibb Company Antitijelo koje sadrži c-terminalnu ekstenziju lakog lanca koja sadrži glutamin, njegovi konjugati, i postupci i primjene
EP3894443A2 (en) 2018-12-12 2021-10-20 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6291673B1 (en) * 1997-10-17 2001-09-18 Purdue Research Foundation Folic acid derivatives
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6291684B1 (en) * 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
CA2449077A1 (en) * 2001-06-01 2002-12-12 Gregory D. Vite Epothilone derivatives
MXPA05001282A (es) * 2002-07-31 2005-04-28 Schering Aktiengsellschaft Conjugados efectores nuevos, procedimiento para su produccion y su uso farmaceutico.
NZ541846A (en) * 2003-01-27 2008-12-24 Endocyte Inc Vitamin receptor binding drug delivery conjugates
US20090004118A1 (en) * 2004-10-07 2009-01-01 Shuming Nie Multifunctional Nanoparticle Conjugates And Their Use

Also Published As

Publication number Publication date
KR20090025267A (ko) 2009-03-10
PE20080102A1 (es) 2008-02-11
TW200813065A (en) 2008-03-16
IL195237A0 (en) 2009-08-03
NO20084752L (no) 2008-12-17
BRPI0712165A2 (pt) 2012-02-14
AU2007267536A1 (en) 2007-12-06
WO2007140298A1 (en) 2007-12-06
EP2023960A1 (en) 2009-02-18
JP2009538350A (ja) 2009-11-05
MX2008014788A (es) 2008-12-02
AR062448A1 (es) 2008-11-12
CA2657276A1 (en) 2007-12-06
CN101495154A (zh) 2009-07-29
US20070275904A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
NO2023022I1 (no) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
SE0402735D0 (sv) Novel compounds
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
TW200626553A (en) Novel compounds
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
TW200639156A (en) New compounds
TW200626158A (en) Naphthaline derivatives
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
TW200637817A (en) 5-aminoindole derivatives
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
TW200800993A (en) Organic compounds
MX2009005912A (es) Derivados de etilamina-fenilo heterociclilo sustituidos, su preparacion y uso como medicamentos.
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone